We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group ...

Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...